We are live on ! Find out more
JJIJ

Johnson & Johnson Innovation - JJDC Portfolio holdings

AUM $978M
1-Year Est. Return 102.17%
This Fund
S&P 500
This Quarter Est. Return
+76.59%
1 Year Est. Return
+102.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$775M
AUM Growth
+$279M
Cap. Flow
-$7.2M
Cap. Flow %
-0.93%
Top 10 Hldgs %
99.57%
Holding
17
New
1
Increased
–
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
LUNG icon
Pulmonx
LUNG
+$276K

Top Sells

Rank Stock Value
1
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$7.38M
2
GNCA
Genocea Biosciences, Inc.
GNCA
+$99K

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Technology 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$270M
$307M 39.62%
3,379,064
– –
ARWR icon
2
Arrowhead Research
ARWR
$12B
$250M 32.27%
3,260,869
– –
PTGX icon
3
Protagonist Therapeutics
PTGX
$8.78B
$49.4M 6.37%
2,449,183
– –
LEGN icon
4
Legend Biotech
LEGN
$3.67B
$45.9M 5.92%
1,629,173
– –
MGTX icon
5
MeiraGTx Holdings
MGTX
$1.1B
$43.9M 5.66%
2,898,550
– –
FUSN
6
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$43.1M 5.56%
3,670,516
– –
PHGE icon
7
BiomX
PHGE
$1.93M
$13.6M 1.76%
11,228
– –
ACET icon
8
Adicet Bio
ACET
$75.8M
$9.31M 1.2%
41,417
– –
PHAS
9
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.4M 0.7%
1,607,044
– –
ALDX icon
10
Aldeyra Therapeutics
ALDX
$94.7M
$4.08M 0.53%
594,834
– –
CSLT
11
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.05M 0.14%
811,295
– –
TCON
12
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$983K 0.13%
4,200
– –
SENS icon
13
Senseonics Holdings Inc
SENS
$255M
$458K 0.06%
26,282
– –
GYRE icon
14
Gyre Therapeutics
GYRE
$664M
$422K 0.05%
8,927
– –
LUNG icon
15
Pulmonx
LUNG
$53.2M
$389K 0.05%
+5,639
New +$276K
PRVB
16
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-574,973
Closed -$7.38M
GNCA
17
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-43,177
Closed -$99K

Similar funds

NNP
Nachman Norwood & Parrott Greenville, South Carolina $984M AUM 33.8% 1-Year Est. Return
BAWC
Black-and-white Capital Los Angeles, California $967M AUM 94.03% 1-Year Est. Return
RP
RR Partners New York $929M AUM 110.28% 1-Year Est. Return
NIA
Northstar Investment Advisors Denver, Colorado $755M AUM 37.8% 1-Year Est. Return
SCM
Snow Capital Management Sewickley, Pennsylvania $703M AUM 76.26% 1-Year Est. Return
EMG
Ellington Management Group Old Greenwich, Connecticut $676M AUM 23.65% 1-Year Est. Return
APA
Allegiant Private Advisors Sarasota, Florida $618M AUM
HFA
Hoover Financial Advisors Malvern, Pennsylvania $562M AUM 37.9% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's Q4 2020 Portfolio in Review

As of Q4 2020, Johnson & Johnson Innovation - JJDC held 17 positions worth $775M, up 56% from $497M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Johnson & Johnson Innovation - JJDC's Q4 2020 filing shows 1 new and 2 closed positions. Its largest new stake was Pulmonx: 5,639 shares worth $389K. The largest sale was Provention Bio, Inc. Common Stock, an estimated $7.38M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

  • Johnson & Johnson Innovation - JJDC's largest Q4 2020 buy was Pulmonx: 5,639 shares worth $389K.
  • Johnson & Johnson Innovation - JJDC fully exited Provention Bio, Inc. Common Stock in Q4 2020, selling an estimated $7.38M.
  • Johnson & Johnson Innovation - JJDC's ten largest holdings make up 100% of its $775M portfolio in Q4 2020.
  • Johnson & Johnson Innovation - JJDC opened 1 new position and closed 2 in Q4 2020.
  • Johnson & Johnson Innovation - JJDC's portfolio value rose 56% quarter-over-quarter to $775M.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q4 2020, filed 9 Feb 2021.